CD8A and colorectal cancer: Furthermore, MSCs improved sensitivity to anti-PD-1 therapy in colorectal cancer by inhibiting PD-1 expression on CD8+ T cells and promoting proliferation of CD8+ T cells by promoting M1 macrophage polarization.